Thermo Electron buys Fisher Scientific International for $10.6B
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Thermo Electron |
Fisher Scientific International |
$10.6B buyout |
Thermo Electron has agreed to buy Fisher Scientific International in a $10.6 billion stock deal, creating a major force in the laboratory supply business. |
|
Merck |
GlycoFi and Abmaxis |
$480M buyout |
Drug giant Merck has acquired two biotechs: GlycoFi for $400M and Abmaxis for $80 million. |
|
Biogen Idec |
Conforma Therapeutics |
$150M buyout, $100M development deal |
Biogen Idec is paying $150M up front to buy Conforma Therapeutics and will pay up to $100Mmore based on the success of Conforma's pipeline of cancer therapies. |
|
Qiagen |
Gentra Systems |
$38M buyout |
The Dutch molecular diagnostics company Qiagen has struck a deal to buy Minneapolis-based Gentra Systems for $38M in cash. |
|
Atrium Biotechnologies |
Amisol |
$6M buyout |
Atrium Biotechnologies is buying personal care products maker Amisol for $6M. |
|
Human Genome Sciences |
BioMed Realty |
$425 million sale/leaseback deal |
HGS has inked a $425M sale/leaseback deal with BioMed Realty on its lab, manufacturing and headquarters facilities. |
|
AstraZeneca |
Abraxis BioScience |
$200M promotion deal, $350M sale |
The companies will share the promotional rights to the cancer drug Abraxane. AZ also announced it will sell its anesthetic and analgesic products to Abraxane for $350M. |
|
SkyePharma |
Kos Pharmaceuticals |
$165M licensing deal |
SkyePharma has inked a $165M licensing deal with Kos Pharmaceuticals for the U.S. marketing rights to Flutiform for asthma. SkyePharma has been seeking a partner on the drug for three years. |
|
Astellas Pharma |
Ilypsa |
$92M licensing deal |
Astellas will pay $92M for the Japanese rights to Ilypsa for a Phase I experimental drug for hyperphosphatemia. |
|
Astellas Pharma |
FibroGen |
$465M development deal |
Astellas will pay $465M in developmental milestones for two of FibroGen's experimental drugs and invest $50M in FibroGen. |
|
Akorn |
Fidia Farmaceutici |
Development deal |
Akorn has signed a deal with Italy's Fidia Farmaceutici to develop four ANDA products. |
|
PPD |
PDL BioPharma |
Development deal |
PPD has struck a deal to develop biomarkers for PDL BioPharma. |
|
Pfizer |
Monogram Biosciences |
$25M investment |
Pfizer will invest $25M into Monogram Biosciences and will collaborate on Monogram's Co-Receptor Tropism Assay. |
|
PerkinElmer |
Spectral Genomics |
Acquisition |
PerkinElmer has acquired the screening and diagnostics company Spectral Genomics for an undisclosed amount. |
|
Sigma-Aldrich |
Iropharm |
Acquisition |
Sigma-Aldrich has acquired Iropharm's custom chemical synthesis facility in Ireland. |